Inclusion of trans women in pre-exposure prophylaxis trials: a review.

Simple item page
dc.contributor.authorEscudero, Daniel
dc.contributor.authorKerr, Thomas
dc.contributor.authorOperario, Don
dc.contributor.authorSocias, Maria E.
dc.contributor.authorSued, Omar
dc.contributor.authorMarshall, Brandon
dc.date.accessioned2024-05-23T10:10:10Z
dc.date.available2024-05-23T10:10:10Z
dc.date.issued2015
dc.description.abstractTrans women are at high-risk of HIV infection. We conducted a review to determine the extent to which trans women were eligible for inclusion in and enrolled into pre-exposure prophylaxis (PrEP) efficacy trials. Out of seven trials analyzing PrEP efficacy, we found that trans women comprised only 1.2% of one trial, and 0.2% of total trial enrollments. Although an additional PrEP trial to determine efficacy among trans women may not be warranted, further research is needed to determine the effectiveness of PrEP in this marginalized population, through observational and feasibility studies. These studies should focus on unique barriers that trans women may experience while obtaining access to PrEP, such as gender discrimination, transphobia, and violence.
dc.identifier.citationDaniel J Escudero, Thomas Kerr, Don Operario, Maria E Socías, Omar Sued, and Brandon DL Marshall. 2015. “Inclusion of trans women in pre-exposure prophylaxis trials: a review.” AIDS Care, 27, 5, Pp. 637-41.
dc.identifier.other10.1080/19716559.2015.1033576
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1032
dc.relation.ispartofseriesAIDS Care, 27(5)
dc.subjectInclusion
dc.subjectTrans Women
dc.subjectPre-exposure Prophylaxis Trials
dc.titleInclusion of trans women in pre-exposure prophylaxis trials: a review.

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
80_2015_Escudero_Inclusion of Trans Women in PrEP trials.pdf
Size:
112.42 KB
Format:
Adobe Portable Document Format
Download

Collections

Articulos científicos